[{"address1": "321 Arsenal Street", "city": "Watertown", "state": "MA", "zip": "02472", "country": "United States", "phone": "339 217 0161", "website": "https://www.iteostherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lymphocytes, and macrophages and to promote the release of cytotoxic granules and antibody-dependent cellular cytotoxicity activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonist program; EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to reverse immunosuppression and restore T cell proliferation in the tumor microenvironment; and EOS-215, a monoclonal antibody which antagonizes triggering receptor expressed on triggering receptor expressed on myeloid cells 2. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts. As of August 28, 2025, iTeos Therapeutics, Inc. operates as a subsidiary of Concentra Biosciences, LLC.", "fullTimeEmployees": 173, "companyOfficers": [], "auditRisk": 7, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1756684800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 10.15, "open": 0.0, "dayLow": 10.15, "dayHigh": 10.15, "regularMarketPreviousClose": 10.15, "regularMarketOpen": 0.0, "regularMarketDayLow": 10.15, "regularMarketDayHigh": 10.15, "payoutRatio": 0.0, "beta": 1.493, "forwardPE": -1.7350427, "volume": 0, "regularMarketVolume": 0, "averageVolume": 1338787, "averageVolume10days": 2068473, "averageDailyVolume10Day": 2068473, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 448684800, "fiftyTwoWeekLow": 4.8, "fiftyTwoWeekHigh": 17.63, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 10.1397, "twoHundredDayAverage": 8.280375, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -61617212, "profitMargins": 0.0, "floatShares": 33493988, "sharesOutstanding": 44205400, "sharesShort": 2061672, "sharesShortPriorMonth": 3069614, "sharesShortPreviousMonthDate": 1752537600, "dateShortInterest": 1755216000, "sharesPercentSharesOut": 0.0466, "heldPercentInsiders": 0.00349, "heldPercentInstitutions": 0.90282995, "shortRatio": 1.34, "shortPercentOfFloat": 0.057800002, "impliedSharesOutstanding": 44205400, "bookValue": 12.903, "priceToBook": 0.78663874, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -202411008, "trailingEps": -4.73, "forwardEps": -5.85, "enterpriseToEbitda": 0.305, "52WeekChange": -0.34768635, "SandP52WeekChange": 0.18469036, "quoteType": "EQUITY", "currentPrice": 10.15, "targetHighPrice": 11.0, "targetLowPrice": 10.0, "targetMeanPrice": 10.35, "targetMedianPrice": 10.05, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 3, "totalCash": 515430016, "totalCashPerShare": 11.66, "ebitda": -202050000, "totalDebt": 5128000, "quickRatio": 7.371, "currentRatio": 7.528, "totalRevenue": 0, "debtToEquity": 1.038, "revenuePerShare": 0.0, "returnOnAssets": -0.18486, "returnOnEquity": -0.34969002, "grossProfits": 0, "freeCashflow": -22141250, "operatingCashflow": -108064000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ITOS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "iTeos Therapeutics, Inc.", "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1595597400000, "regularMarketChange": 0.0, "regularMarketDayRange": "10.15 - 10.15", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1338787, "fiftyTwoWeekLowChange": 5.3499994, "fiftyTwoWeekLowChangePercent": 1.1145831, "fiftyTwoWeekRange": "4.8 - 17.63", "fiftyTwoWeekHighChange": -7.4799995, "fiftyTwoWeekHighChangePercent": -0.4242768, "fiftyTwoWeekChangePercent": -34.768635, "earningsTimestamp": 1754483400, "earningsTimestampStart": 1754483400, "earningsTimestampEnd": 1754483400, "isEarningsDateEstimate": false, "regularMarketChangePercent": 0.0, "regularMarketPrice": 10.15, "epsTrailingTwelveMonths": -4.73, "epsForward": -5.85, "epsCurrentYear": -3.84, "priceEpsCurrentYear": -2.643229, "fiftyDayAverageChange": 0.010299683, "fiftyDayAverageChangePercent": 0.0010157778, "twoHundredDayAverageChange": 1.8696251, "twoHundredDayAverageChangePercent": 0.22578992, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-07-24", "averageAnalystRating": "3.0 - Hold", "cryptoTradeable": false, "corporateActions": [{"header": "Delisting", "message": "ITOS is delisted effective Sep. 8, 2025", "meta": {"eventType": "DELISTING", "dateEpochMs": 1757304000000}}], "regularMarketTime": 1756411201, "exchange": "NGM", "messageBoardId": "finmb_663087242", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "longName": "iTeos Therapeutics, Inc.", "displayName": "iTeos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-09-06"}]